Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp459 | Other diseases of bone and mineral metabolism | ECTS2013

Correlates of tissue mineral density of bone samples from total hip arthroplasty patients with type 2 diabetes: an ex vivo study

Pritchard Janet , Papaioannou Alexandra , Hurtig Mark , Giangregorio Lora , Atkinson Stephanie , Beattie Karen , Adachi J.D. , DeBeer Justin , Winemaker Mitchell , Avram Victoria , Schwarcz Henry

Introduction: Fracture risk is greater for adults with type 2 diabetes (T2D), despite normal or higher areal bone mineral density (aBMD) compared to controls. Tissue mineral density (TMD), measured by microCT, is more representative of actual mineral density than in vivo aBMD. The aim of this study was to determine whether TMD is greater in adults with T2D, and to investigate the correlates of TMD in adults with T2D.Methods: Using proximal femur...

ba0007oc20 | (1) | ICCBH2019

Identifying the role of NBAS in bone fragility using zebrafish and exploring therapeutic targets to reverse NBAS activity

Balasubramanian Meena , Baxendale Sarah , Roehl Henry

Background: We discovered that variants in NBAS (Neuroblastoma Amplified Sequence Gene) known to be associated with acute liver failure are also responsible for skeletal abnormalities. This work was published as a novel cause of bone fragility [Balasubramanian et al., 2017]. NBAS role in bone fragility provides an opportunity to use tractable animal research to advance understanding of mechanism and identify potential new treatments. This would be beneficial to patien...

ba0006p200 | (1) | ICCBH2017

The platform of expertise for rare diseases Paris-Sud: an innovative model for gathering reference centers and improving care for rare diseases

Usardi Alessia , Henry Charlotte , Habib Christophe , Fernandez Isabelle , Debza Yahya , Darce Martha , Stoeva Radka , Labrune Philippe , Linglart Agnes

Introduction: The platform of expertise for rare diseases Paris-Sud is an organization created at the end of 2014. It brings together 21 reference centers for rare diseases of the university hospitals Paris-Sud, 12 diagnostic and research laboratories, a biological resource center and several patient associations.Methods: A multidisciplinary team (a communication officer, a bio-informatician, a geneticist, clinical research associates, an administrative ...

ba0001pp436 | Osteoporosis: treatment | ECTS2013

Bone mineral density changes in patients with prior fracture suboptimally treated with a bisphosphonate: results from denosumab (DMAb)/ibandronate and DMAb/risedronate trials

Recknor Christopher , Roux Christian , Ho Pei-Ran , Hall Jesse , Bone Henry , Bonnick Sydney , van den Bergh Joop , Ferreira Irene , Wagman Rachel , Brown Jacques P

: In osteoporosis, poor adherence to bisphosphonate (BP) therapy is common, and is associated with poor outcomes and increased treatment costs (Siris 2006; Recker 2005). Although compliance is improved with monthly vs weekly dosing (Reginster 2008), no evidence suggests cycling through BP agents offers therapeutic benefit, assessed by bone mineral density (BMD). In two randomized, open-label studies in postmenopausal women aged ≥55 years previously treated with, but subo...

ba0003pp357 | Osteoporosis: treatment | ECTS2014

In postmenopausal women previously treated with an oral bisphosphonate and at higher risk of fracture, denosumab significantly increases bone mineral density compared with ibandronate and risedronate

Brown Jacques P , Bolognese Michael A , Ho Pei-Ran , Roux Christian , Bone Henry G , Bonnick Sydney L , van den Bergh Joop , Ferreira Irene , Ghelani Prayashi , Dakin Paula , Wagman Rachel B , Recknor Christopher

Low bone mineral density (BMD) is an important and modifiable risk factor for fracture in postmenopausal women with osteoporosis. Denosumab (DMAb) shows a stronger relationship between BMD increases and antifracture efficacy than oral bisphosphonate (BP) therapies. Subjects who remain at higher risk of fracture despite current BP therapy need treatment. In two studies, DMAb significantly increased BMD and decreased bone turnover markers vs a BP (ibandronate (IBN) or risedronat...

ba0001pp66 | Bone development/growth and fracture repair | ECTS2013

The P2Y2 receptor restrains BMD during development

Syberg Susanne , Ellegaard Maria , Schwarz Peter , Jorgensen Niklas Rye

The P2Y2 receptor is a G-protein-coupled receptor and the natural ligands (ATP/UTP) strongly inhibit mineralized bone nodule formation by osteoblasts in vitro. We have earlier shown that overexpression of the P2Y2 receptor in vivo resulted in decreased bone mineral density (BMD), partially due to increased bone resorption, but also decreased formation (detected by serum bone markers and bone histomorphometry).This ...

ba0001pp237 | Cell biology: osteocytes | ECTS2013

Nucleotide and mechanically induced ATP release pathways in osteocytes

Kringelbach Tina M , Novak Ivana , Schwarz Peter , Jorgensen Niklas Rye

Background: We have previously shown that MLO-Y4 osteocytes express a number of P2 receptors, respond to a broad range of nucleotides (e.g. UTP) by increasing intracellular calcium concentration and release ATP upon both mechanical and UTP stimulation. The aim of this study therefore is to investigate how the osteocytes release ATP and whether there is a difference in release pathway depending on the type of stimulus.Methods: ATP release was investigated...

ba0001pp285 | Muscle, physical activity and bone | ECTS2013

Prolonged botulinum toxin type A-induced muscle paralysis results in loss of bone mineral density and bone strength in young female rats

Ellegaard Maria , Syberg Susanne , Jorgensen Niklas Rye , Schwarz Peter

Transient paralysis by a single injection of botulinum toxin type A (Botox) in rodents has been shown to cause local bone loss of the affected leg. The animals regain function of the leg within 3–4 weeks and bone loss slowly recovers. The duration of the paralysis is dose-dependent. However, higher doses of Botox cause weight loss and decreased activity level.Aim of study was to investigate whether repeated injections of low-dose Botox could induce ...

ba0001pp387 | Osteoporosis: pathophysiology and epidemiology | ECTS2013

Sclerostin associated with vertebral bone marrow fat in older men but not women

Ma Vivian , Li Xiaojuan , Sigurdsson Sigurdur , Eriksdottir Gudny , Hauksdottir Alda , Palermo Lisa , Hue Trisha , Lang Thomas , Harris Tamara , Rosen Clifford , Vittinghoff Eric , Siggeirsdottir Kristin , Sigurdsson Gunnar , Oskarsdottir Diana , Gudnason Vilmundur , Schwartz Ann

Previous studies found a negative correlation between vertebral bone marrow fat (MF) and bone density (BMD). Proposed mechanisms for this include i) a shift in stem cell lineage allocation from osteoblasts towards adipocytes, and ii) an increase in osteoclast-promoting cytokines with greater MF. However, little is known about the relationship between MF and bone markers. To assess these relationships in older adults, we used data from the AGES-Reykjavik cohort. MF was measured...